Popular Oral Drug for Diabetes May Hold 'Intriguing' Side Benefit

(MedPage Today) — Type 2 diabetes patients who started taking SGLT2 inhibitors had a slightly lower risk of autoimmune rheumatic diseases compared to those who started taking sulfonylureas, according to a large Korean retrospective study. On a median follow-up…